Literature DB >> 33410258

Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.

Janice L Berliner1, Shelly A Cummings2, Brittany Boldt Burnett3, Charité N Ricker4.   

Abstract

Cancer risk assessment and genetic counseling for hereditary breast and ovarian cancer (HBOC) are a communication process to inform and prepare patients for genetic test results and the related medical management. An increasing number of healthcare providers are active in the delivery of cancer risk assessment and testing, which can have enormous benefits for enhanced patient care. However, genetics professionals remain key in the multidisciplinary care of at-risk patients and their families, given their training in facilitating patients' understanding of the role of genetics in cancer development, the potential psychological, social, and medical implications associated with cancer risk assessment and genetic testing. A collaborative partnership of non-genetics and genetics experts is the ideal approach to address the growing number of patients at risk for hereditary breast and ovarian cancer. The goal of this practice resource is to provide allied health professionals an understanding of the key components of risk assessment for HBOC as well as the use of risk models and published guidelines for medical management. We also highlight what patient types are appropriate for genetic testing, what are the most appropriate test(s) to consider, and when to refer individuals to a genetics professional. This practice resource is intended to serve as a resource for allied health professionals in determining their approach to delivering comprehensive care for families and individuals facing HBOC. The cancer risk and prevalence figures in this document are based on cisgender women and men; the risks for transgender or non-binary individuals have not been studied and therefore remain poorly understood.
© 2021 National Society of Genetic Counselors.

Entities:  

Keywords:  cancer risk assessment; cascade testing; family history; genetic counseling; genetic testing

Year:  2021        PMID: 33410258     DOI: 10.1002/jgc4.1374

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  3 in total

1.  Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO).

Authors:  Yusuke Kobayashi; Kenta Masuda; Akira Hiraswa; Kazuhiro Takehara; Hitoshi Tsuda; Yoh Watanabe; Katsutoshi Oda; Satoru Nagase; Masaki Mandai; Aikou Okamoto; Nobuo Yaegashi; Mikio Mikami; Takayuki Enomoto; Daisuke Aoki; Hidetaka Katabuchi
Journal:  J Gynecol Oncol       Date:  2022-07-18       Impact factor: 4.756

Review 2.  Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.

Authors:  Rinat Bernstein-Molho; Eitan Friedman; Ella Evron
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

3.  Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.

Authors:  Julie O Culver; Yael Freiberg; Charité Ricker; Jacob G Comeaux; Emmeline Y Chang; Victoria Banerjee; Duveen Sturgeon; Ilana Solomon; Josie Kagey; Mariana G Dobre; Joseph Carey; Azadeh Carr; Stephanie Cho; Janice Lu; Irene M Kang; Ketan Patel; Alicia Terando; Jason C Ye; Ming Li; Caryn Lerman; Darcy Spicer; Maria Nelson
Journal:  Ann Surg Oncol       Date:  2022-09-26       Impact factor: 4.339

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.